{
    "root": "809025db-0f4b-4ab7-bfd9-470887fa5f3a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin Calcium",
    "value": "20250326",
    "ingredients": [
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : • reduce risk : ○ myocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd ○ myocardial infarction stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd ○ non-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd • adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : ○ adults primary hyperlipidemia . ○ adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . • adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . • adjunct diet treatment adults : ○ primary dysbetalipoproteinemia ○ hypertriglyceridemia",
    "contraindications": "• take orally daily without food ( 2.1 ) . • assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium tablets , adjust necessary ( 2.1 ) . • adults ( 2.2 ) : ○ recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . ○ patients requiring ldl-c reduction > 45 % may start 40 mg daily . • pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . • pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . • full prescribing information atorvastatin calcium tablets modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "atorvastatin calcium tablets , usp available containing atorvastatin calcium , usp equivalent 10 mg , 20 mg , 40 mg 80 mg atorvastatin . 10 mg tablets white off-white , film-coated , oval shaped tablet plain one side debossed '11 ' side . available follows : bottles 90s count child resistant closure , ndc 16571-136-09 bottles 500s count child resistant closure , ndc 16571-136-50 bottles 1000s count child resistant closure , ndc 16571-136-10 20 mg tablets white off-white , film-coated , oval shaped tablet plain one side debossed '114 ' side . available follows : bottles 90s count child resistant closure , ndc 16571-137-09 bottles 500s count child resistant closure , ndc 16571-137-50 bottles 1000s count child resistant closure , ndc 16571-137-10 40 mg tablets white off-white , film-coated , oval shaped tablet plain one side debossed '115'on side . available follows : bottles 90s count child resistant closure , ndc 16571-138-09 bottles 500s count child resistant closure , ndc 16571-138-50 bottles 1000s count child resistant closure , ndc 16571-138-10 80 mg tablets white off-white , film-coated , oval shaped tablet plain one side debossed '116'on side . available follows : bottles 90s count child resistant closure , ndc 16571-139-09 bottles 500s count child resistant closure , ndc 16571-139-50 bottles 1000s count child resistant closure , ndc 16571-139-10 storage store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "acute liver failure decompensated cirrhosis [ ( 5.3 ) ] hypersensitivity atorvastatin excipients atorvastatin . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin calcium tablets are indicated:\n                  • To reduce the risk of:\n                    ○ Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                    ○ MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                    ○ Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                  • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                    ○ Adults with primary hyperlipidemia.\n                    ○ Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                  • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                  • As an adjunct to diet for the treatment of adults with:\n                    ○ Primary dysbetalipoproteinemia\n                    ○ Hypertriglyceridemia",
    "contraindications_original": "• Take orally once daily with or without food ( 2.1 ). • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). • Adults ( 2.2 ): ○ Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. ○ Patients requiring LDL-C reduction >45% may start at 40 mg once daily. • Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). • Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). • See full prescribing information for atorvastatin calcium tablets dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions_original": "Atorvastatin calcium tablets, USP are available containing atorvastatin calcium, USP equivalent to 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin.\n                  The 10 mg tablets are white to off-white, film-coated, oval shaped tablet plain on one side and debossed with '11' on other side. They are available as follows:\n                  Bottles of 90s count with child resistant closure,                                                               NDC 16571-136-09\n                  Bottles of 500s count with child resistant closure,                                                             NDC 16571-136-50\n                  Bottles of 1000s count with child resistant closure,                                                           NDC 16571-136-10\n                  The 20 mg tablets are white to off-white, film-coated, oval shaped tablet plain on one side and debossed with '114' on other side. They are available as follows:\n                  Bottles of 90s count with child resistant closure,                                                              NDC 16571-137-09\n                  Bottles of 500s count with child resistant closure,                                                            NDC 16571-137-50\n                  Bottles of 1000s count with child resistant closure,                                                          NDC 16571-137-10\n                  The 40 mg tablets are white to off-white, film-coated, oval shaped tablet plain on one side and debossed with '115'on other side. They are available as follows:\n                  Bottles of 90s count with child resistant closure,                                                              NDC 16571-138-09\n                  Bottles of 500s count with child resistant closure,                                                            NDC 16571-138-50\n                  Bottles of 1000s count with child resistant closure,                                                          NDC 16571-138-10\n                  The 80 mg tablets are white to off-white, film-coated, oval shaped tablet plain on one side and debossed with '116'on other side. They are available as follows:\n                  Bottles of 90s count with child resistant closure,                                                              NDC 16571-139-09\n                  Bottles of 500s count with child resistant closure,                                                            NDC 16571-139-50\n                  Bottles of 1000s count with child resistant closure,                                                          NDC 16571-139-10\n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)]\n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported [see Adverse\n                        Reactions (6.2)]."
}